STTK
NASDAQShattuck Labs Inc.
News · 26 weeks60+92%
2025-12-282026-06-21
Mix3890d
- Insider19(50%)
- SEC Filings10(26%)
- Other6(16%)
- Offering2(5%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Ashiya Mona4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Orbimed Advisors Llc4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.SCHEDULE 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)
- INSIDERDirector Siegall Clay B bought $250,000 worth of shares (62,500 units at $4.00), increasing direct ownership by 24% to 318,608 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECSEC Form 8-K filed by Shattuck Labs Inc.8-K - Shattuck Labs, Inc. (0001680367) (Filer)
- SECSEC Form 424B5 filed by Shattuck Labs Inc.424B5 - Shattuck Labs, Inc. (0001680367) (Filer)
- PRShattuck Labs, Inc. Announces Pricing of $75 Million Public OfferingAUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded war
- INSIDERSEC Form 4 filed by Director Orbimed Advisors Llc4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashiya Mona4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECSEC Form 424B5 filed by Shattuck Labs Inc.424B5 - Shattuck Labs, Inc. (0001680367) (Filer)
- SECShattuck Labs Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - Shattuck Labs, Inc. (0001680367) (Filer)
- PRShattuck Labs, Inc. Announces Proposed Public OfferingAUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Shattuck expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its com
- PRShattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial UpdateAUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced it has received notices to exercise totaling approximately 50.6 million common stock warrants to date, representing approximately 96% of the warrants issued in the Company's August 4, 2025 private placement. The exercise of these warrants is expected to result in aggregate gross proceeds of approximately $54.9 million. As of March 31, 2026, the
- PRShattuck Labs Announces Phase 1 Results for SL-325Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/kg and higherWell tolerated with a favorable safety profile consistent with the TL1A inhibitor classNo evidence of DR3 agonismRECEPTIVE-CD1 Phase 2b clinical trial in patients with Crohn's disease expected to initiate in the third quarter of 2026 Lead bispecific product candidate, SL-846 (DR3xIL-23R), currently being evaluated in IND-enabling toxicology studies; Phase 1 initiation expected in the first half of 2027 AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, I
- PRShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that it will host an investor call and webcast on Monday, June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, including safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic and immunogenicity results and provide a pipeline update. The event will feature presentations by members of Shat
- INSIDERSEC Form 4 filed by Director Golumbeski George4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashiya Mona4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Baker Daniel G.4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Siegall Clay B4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Gibson Neil W4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERSEC Form 4 filed by Director Boudreau Helen M4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- SECSEC Form 8-K filed by Shattuck Labs Inc.8-K - Shattuck Labs, Inc. (0001680367) (Filer)
- INSIDERDirector Siegall Clay B was granted 128,054 shares, increasing direct ownership by 100% to 256,108 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
- INSIDERChief Technical Officer Shukla Abhinav A. was granted 5,122 shares, increasing direct ownership by 6% to 86,380 units (SEC Form 4)4 - Shattuck Labs, Inc. (0001680367) (Issuer)
STTK FAQ
7 questionsWhat does Shattuck Labs Inc. do?
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.Where does STTK stock trade?
Shattuck Labs Inc. (STTK) is listed on NASDAQ.What sector and industry is STTK in?
Shattuck Labs Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Shattuck Labs Inc. go public?
Shattuck Labs Inc. (STTK) completed its IPO in 2020.What are analysts saying about STTK?
Shattuck Labs Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-04-27.What companies are similar to STTK?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare STTK side-by-side with any of them on Quantisnow.How can I track STTK on Quantisnow?
Quantisnow aggregates Shattuck Labs Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STTK to receive live email and push alerts on every new disclosure.